Physician profile
Anna M Duncan
NPI 1407882871
$3,489.55
in general payments reported to CMS, 2019-2025
27 companies · $348 in 2025
The $348 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.86 · 2020: $165 · 2021: $164 · 2022: $863 · 2023: $810 · 2024: $1,091 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,249.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $970.77 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $351.04 | 2020-2024 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $331.75 | 2022-2024 | Farxiga, Airsupra |
| Abbvie INC. | $298.64 | 2021-2025 | Ubrelvy |
| Glaxosmithkline, LLC. | $230.30 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $216.94 | 2022-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.00 | 2022-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $113.20 | 2022-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $101.02 | 2019-2022 | |
| Pfizer INC. | $83.83 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $79.10 | 2024-2025 | |
| Medtronic, INC. | $76.47 | 2022-2024 | Intellis Adaptivestim |
| Sanofi-Aventis U.S. LLC | $64.92 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $53.68 | 2024 | Rexulti |
| Amarin Pharma, INC. | $51.33 | 2022-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $47.47 | 2024-2025 | Korlym |
| Exact Sciences Corporation | $37.18 | 2023-2024 | Cologuard Collection Kit |
| Alexion Pharmaceuticals, INC. | $31.93 | 2022-2023 | Strensiq |
| C2n Diagnostics, LLC | $27.56 | 2025 | Precivityad2 |
| Phathom Pharmaceuticals, INC. | $25.14 | 2023 | Voquezna |
| Harmony Biosciences LLC | $22.05 | 2023 | Wakix |
| Alkermes, INC. | $20.46 | 2019 | |
| Insulet Corporation | $19.75 | 2021 | |
| Supernus Pharmaceuticals, INC. | $18.73 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.66 | 2022 | |
| Xeris Pharmaceuticals, INC. | $16.10 | 2024 | Keveyis |
| Allergan, INC. | $13.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Duncan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.